MIMS® creates a drainage channel to reduce IOP in Glaucoma patients, ensuring a long-lasting safe and controlled fluid flow, no stitches, eye-patch, implant or stent. It is designed to reduce the caring costs of Glaucomatous patients’ through simplicity, low cost, fewer post-surgical complications and less hospitalization.

•	A novel Glaucoma treatment
•	Leaves nothing behind (stent-less) thus lowering the risk of complications
•	Can be easily combined with Cataract surgery
•	Medication-sparing which improves patients' quality of life



Health Care

Medical Devices

Therapeutics

Sanoculis Ltd.

Sanoculis Ltd.'s headquarters in Kiryat Ono, Israel

Description

People (1)

Adam Tarif

Jobs